MoonLake Immunotherapeutics (MLTX) Net Cash Flow (2021 - 2026)

MoonLake Immunotherapeutics' Net Cash Flow history runs 6 years deep, the most recent figure standing at -$35.5 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 138.96% year-over-year to -$35.5 million; the TTM figure through Mar 2026 stood at $26.2 million (up 114.03% YoY), while the FY2025 annual figure was $153.0 million, up 156.48% from the prior year.
• Net Cash Flow was -$35.5 million for Q1 2026 at MoonLake Immunotherapeutics, down from -$16.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $451.8 million in Q2 2023 to a low of -$195.7 million in Q4 2024.
• Historically, Net Cash Flow has averaged $17.0 million across 5 years, with a median of $7.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Net Cash Flow sank 3266.85% in 2022, then jumped 7962.69% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$1.7 million in 2022, then surged by 7962.69% to $132.9 million in 2023, then tumbled by 247.18% to -$195.7 million in 2024, then soared by 91.66% to -$16.3 million in 2025, then slumped by 117.93% to -$35.5 million in 2026.
• The last three Net Cash Flow figures came in at -$35.5 million (Q1 2026), -$16.3 million (Q4 2025), and $44.3 million (Q3 2025), per Business Quant data.